Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.0112.01%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 57.50K | 278.60K | 14.30K | 109.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 57.50K | 278.60K | 14.30K | 109.70K |
| Cost of Revenue | 323.20K | 858.90K | 380.70K | 548.20K | 405.40K |
| Gross Profit | -323.20K | -801.40K | -102.00K | -533.90K | -295.60K |
| SG&A Expenses | 831.10K | 874.20K | 874.90K | 1.74M | 460.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.17M | 1.73M | 1.26M | 2.29M | 865.60K |
| Operating Income | -1.17M | -1.68M | -976.90K | -2.27M | -755.90K |
| Income Before Tax | -1.32M | -1.85M | -1.16M | -2.40M | -1.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.32M | -1.85M | -1.16M | -2.40M | -1.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 12.30K | 37.70K | 21.50K | -- | -- |
| Net Income | -1.31M | -1.81M | -1.14M | -2.40M | -1.01M |
| EBIT | -1.17M | -1.68M | -976.90K | -2.27M | -755.90K |
| EBITDA | -1.17M | -1.68M | -976.50K | -2.27M | -753.70K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 420.28M | 420.28M | 420.28M | 420.29M | 419.91M |
| Average Diluted Shares Outstanding | 420.28M | 420.28M | 420.28M | 420.29M | 419.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |